Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21861
Full metadata record
DC FieldValueLanguage
dc.contributor.authorvan der Veen, Sterre-
dc.contributor.authorZutt, Rodi-
dc.contributor.authorKlein, Christine-
dc.contributor.authorMarras, Connie-
dc.contributor.authorBerkovic, Samuel F-
dc.contributor.authorCaviness, John N-
dc.contributor.authorShibasaki, Hiroshi-
dc.contributor.authorde Koning, Tom J-
dc.contributor.authorTijssen, Marina A J-
dc.date2019-10-04-
dc.date.accessioned2019-10-07T21:40:26Z-
dc.date.available2019-10-07T21:40:26Z-
dc.date.issued2019-11-
dc.identifier.citationMovement disorders : official journal of the Movement Disorder Society 2019; 34(11): 1602-1613en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21861-
dc.description.abstractGenetically determined myoclonus disorders are a result of a large number of genes. They have wide clinical variation and no systematic nomenclature. With next-generation sequencing, genetic diagnostics require stringent criteria to associate genes and phenotype. To improve (future) classification and recognition of genetically determined movement disorders, the Movement Disorder Society Task Force for Nomenclature of Genetic Movement Disorders (2012) advocates and renews the naming system of locus symbols. Here, we propose a nomenclature for myoclonus syndromes and related disorders with myoclonic jerks (hyperekplexia and myoclonic epileptic encephalopathies) to guide clinicians in their diagnostic approach to patients with these disorders. Sixty-seven genes were included in the nomenclature. They were divided into 3 subgroups: prominent myoclonus syndromes, 35 genes; prominent myoclonus syndromes combined with another prominent movement disorder, 9 genes; disorders that present usually with other phenotypes but can manifest as a prominent myoclonus syndrome, 23 genes. An additional movement disorder is seen in nearly all myoclonus syndromes: ataxia (n = 41), ataxia and dystonia (n = 6), and dystonia (n = 5). However, no additional movement disorders were seen in related disorders. Cognitive decline and epilepsy are present in the vast majority. The anatomical origin of myoclonus is known in 64% of genetic disorders: cortical (n = 34), noncortical areas (n = 8), and both (n = 1). Cortical myoclonus is commonly seen in association with ataxia, and noncortical myoclonus is often seen with myoclonus-dystonia. This new nomenclature of myoclonus will guide diagnostic testing and phenotype classification. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.en_US
dc.language.isoeng-
dc.subjectgeneticsen_US
dc.subjecthyperekplexiaen_US
dc.subjectmyoclonic epilepsyen_US
dc.subjectmyoclonusen_US
dc.subjectnomenclatureen_US
dc.titleNomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleMovement disorders : official journal of the Movement Disorder Societyen_US
dc.identifier.affiliationDepartment of Neurology, University Groningen, University Medical Center Groningen, Groningen, Netherlandsen_US
dc.identifier.affiliationDepartment of Neurology, Haga Teaching Hospital, The Hague, The Netherlandsen_US
dc.identifier.affiliationEpilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Neurology, University Groningen, University Medical Center Groningen, Groningen, Netherlandsen_US
dc.identifier.affiliationDepartment of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlandsen_US
dc.identifier.affiliationInstitute of Neurogenetics, University of Lübeck, Lübeck, Germanyen_US
dc.identifier.affiliationEdmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canadaen_US
dc.identifier.affiliationDepartment of Neurology, Mayo Clinic, Scottsdale, Arizona, USAen_US
dc.identifier.affiliationKyoto University Graduate School of Medicine, Kyoto, Japanen_US
dc.identifier.affiliationDepartment of Neurology, University Groningen, University Medical Center Groningen, Groningen, Netherlandsen_US
dc.identifier.doi10.1002/mds.27828en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-5783-571Xen_US
dc.identifier.orcid0000-0003-4580-841Xen_US
dc.identifier.pubmedid31584223-
dc.type.austinJournal Article-
dc.type.austinReview-
local.name.researcherBerkovic, Samuel F
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptEpilepsy Research Centre-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Nov 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.